deliv modest core revenue better ep upsid
balanc growth across end-market product line biopharma solid
comp trend still slow think biopharma con
moder see limit room margin expans keep us hold
acceler capit deploy upsid risk rais
ep respect pt move
initi outlook line initi ep outlook bracket
consensu view impli growth driven ebit growth point
msd organ growth stabl biopharma industri demand stepped-up buyback
ep slightli lower interest expens off-set advers effect higher
recap modest core rev ep beat growth incl extra day
reflect balanc growth across board better academ demand
notori lumpi account upsid vs model
biopharma healthi aid rebound us mid/larg pharma demand
sluggish year two-yr stack biopharma core growth still deceler
vs industri flat tough comp geograph
america rebound us pharma eu remain strong asia
w/ china howev op leverag fairli limit opm surpris
uptick opex y/i partial off-set better mix
focu tax reform capit deploy prioriti tax reform give
enhanc tax-effici access substanti ou cash hoard
see strateg asset stress proceed patient maxim roi top
prioriti remain organ re-invest follow shore bs return cash
holder buy-back activ step-up meaning like level
dividend seem unlik chang disciplin philosophi
maintain view share impli premium average
near histor peak level backdrop moder pharma trend slow
core revs/ep growth see risk/reward balanc
pt repres discount horizon dcf model impli ev
ebitda ufcf risk margin headwind biopharma slowdown
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
share repurchas
ep opm expans
ep op margin expans
nopat compound-annual-growth-rate next decad
price impli ev ebitda
sustain strength global biopharmaceut
wat core focu three analyt technolog market
nich liquid chromatographi mass spectrometri
thermal analysi astut concentr asset
util disciplin capit redeploy
philosophi contribut above-averag
profit industry-lead profil
cautiou wat exposur
rev end-market
believ could continu deceler
repatri new tax reform
acquiti uplc uptak qa/qc set
acceler share repurchas
price multipl ev ebitda
biopharma cycl slow
stepped-up invest support clinic health
heighten competit pressur lc mass spec
price multipl ev ebitda
page
pleas see import disclosur inform page report
